335349-58-1

Basic information

• Product Name: 4-Iodo-5-methyl-2-nitro-phenylamine
• Synonyms: 4-Iodo-5-methyl-2-nitro-phenylamine;4-Iodo-5-methyl-2-nitroaniline
• CAS NO: 335349-58-1
• Molecular Formula: C₇H₇IN₂O₂
• Molecular Weight: 278.04715
• Mol File: 335349-58-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Iodo-5-methyl-2-nitro-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Iodo-5-methyl-2-nitro-phenylamine(335349-58-1)
• EPA Substance Registry System: 4-Iodo-5-methyl-2-nitro-phenylamine(335349-58-1)

Safety Data

• Hazardous Substances Data: 335349-58-1(Hazardous Substances Data)

Upstream product

• 578-46-1 5-methyl-2-nitroaniline 
• 97113-39-8 N-(4-iodo-3-methylphenyl)acetamide 

Downstream Products

• 97113-23-0 (2-Chloro-3-methyl-6-nitro-4-piperidin-1-yl-benzylamino)-acetic acid ethyl ester 
• 96336-70-8 (2-Amino-5-methyl-4-piperidin-1-yl-benzylamino)-acetic acid ethyl ester 
• 97112-74-8 5-Methyl-2-nitro-4-piperidin-1-yl-benzonitrile 
• 97113-19-4 5-Methyl-2-nitro-4-piperidin-1-yl-benzylamine 
• 97112-60-2 4-iodo-5-methyl-2-nitrobenzonitrile 

Relevant articles and documents

KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT

Compounds that function as kinase inhibitors are provided. The kinase inhibitors can have any structure of the formulae provided herein, such as shown for Compounds 1-4. A pharmaceutical composition can include: the compound of one of the embodiments; and

Crystal packing: An examination of the packing of molecules approximately isosteric with 4,5-dichlorophthalic anhydride

The crystal structures of five 5,6-disubstituted benzofurazan 1-oxides are presented and compared with five previously reported structures: three polymorphs of 5,6-dichlorobenzofurazan 1-oxide plus 4,5-dichloro- and 4,5-dibromophthalic anhydride. All but one of these compounds pack with similar two-dimensional layers. The benzofurazan oxides all show disorder about a crystallographic twofold or pseudo-twofold axis. In addition, six complexes of phthalic anhydride and benzofurazan oxides are reported. With the packing in the complexes principally directed by the π complexing, the disorder, invariably found in the uncomplexed benzofurazan oxides, is diminished, and, in two cases, eliminated.

Glutamate receptor antagonists

The present invention relates to compounds of with a base structure of formula 1 The compounds of formula I are shown to have activity as metabotropic glutamate receptor antagonists.

Cyclic guanidines. 17. Novel (N-substituted amino)imidazo[2,1-b]quinazolin-2-ones: Water-soluble platelet aggregation inhibitors

A series of novel 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one derivatives substituted with a secondary amino group has been prepared and tested for the activities of inhibiting platelet aggregation in rats in vitro and ex vivo. Most of the compounds